Happy to share with you our review on ALCOHOL-ASSOCIATED HEPATITIS, published today in the @NEJM. We dedicate it to all our patients. We will continue to work together to beat it. @Dr_Vijay_Shah @juanpabloarab https://t.co/Sq4QX806Pq #LiverTwitter #MedTwitter

📢Autoantibodies matter in #MASLD Global study of 460 biopsy-proven cases, ANA or ASMA positivity independently predicted: ⚠️ 3.9× higher risk of liver decomp ⚰️ 2.5× higher risk of death 📉 Histologic AIH features didn’t correlate with outcomes 👉 https://t.co/kxeEaeoVI1

Data from today’s Global Burden of Disease Report in The Lancet: Mortality is declining worldwide, yet young adults in the USA are dying at increasing rates, mainly due to alcohol, drugs, and violence. A silent epidemic that demands urgent action. https://t.co/LeezVngfnw

https://t.co/roKFL8FjVA

Honored to speak today in Porto invited by my friend @JosPresa3 about controversies in MASLD and MetALD terminology. Here is a preview slide and the 5 main controversies. SLD meetings emphasize MASLD, talk about MetALD, while ALD gets little attention. This imbalance matters.

I’ve witnessed patients get better… even with a placebo. It’s not “just in their heads.” The placebo effect has real biology: powerful brain-body mechanisms that can reduce pain and anxiety. 👇 Check out this simple figure below.

📢We are pleased to announce publication of the EASO Algorithm for the pharmacological treatment of obesity and its complications in Nature Medicine. Obesity is an adiposity-based chronic disease (ABCD); assess severity and complications to guide treatment https://t.co/HsbJ3Vwl75

(Sunday pic #125). This summer I was in Gambia, a country called “The smiling coast of Africa”. These kids proved it.

@MajaThiele @briantleemd @MzamoMbelle @PoseElisa @rabataller @AleksanderKrag Tracking alcohol use is vital when sustained abstinence is key. Biomarkers can help: 💧 Urinary EtG: useful but short half-life, risk of false positives (esp. kidney dysfunction) 🩸PEth: more reliable, no false positives, can even support diagnosis when alcohol use is denied.

When you get defensive about feedback, you fail twice. You fail to learn today, and you fail to encourage people to keep teaching you tomorrow. If you can't handle the truth, people stop telling you the truth. A key to growth is showing that you're coachable.

Proud to share our new global MASLD/MASH consensus in @AGA_Gastro. This was an international effort by experts in hepatology, endocrinology, primary care, and patient advocacy. The article provides unified, practical guidance for diagnosis, risk stratification, and treatment,

The @NEJM just reported impressive weight loss with Orforglipron, the first oral small-molecule GLP-1 receptor agonist. No more injections needed! 💊 https://t.co/gRxX9IACSS

Is sharing a bottle of wine every evening really harmless? 🍷There are adverse effects on the brain, liver, heart and even ageing – Cutting back, even a little, can make a real difference. @EASLnews @Inst_of_Liver @EASLedu @rabataller https://t.co/C3guXFExvw

The new #LancetCommission obesity definitions show dramatic differences in risk: 🏈 Athlete, BMI 32—WHO called it class I obesity; now “no obesity” 👵 Older woman, BMI 27+diabetes—WHO overweight; now stage 2 clinical obesity 👩 Woman, BMI 33+prediabetes—WHO class I; now stage 1

Repetitive negative thinking is associated with cognitive decline. Stay positive.

Insightful commentary in @Nature about rapid weight loss with GLP-1 meds which can lead to significant muscle loss or even #sarcopenia. Muscle-preserving strategies, exercise, adequate protein (~1.2-1.6 g/kg/d), creatine, and promising new agents like #bimagrumab and myostatin

New research - Phosphatidylethanol and self-reported alcohol intake to subclassify in individuals at risk of steatotic liver disease: an analysis of data from a prospective cohort study https://t.co/cqyMwtuQUI #LiverTwitter #MedTwitter @AleksanderKrag

🟣GDF15 is associated with hepatocellular senescence and correlates with mortality in patients with alcohol-associated hepatitis 🔓#OpenAccess at👉 https://t.co/vKvh4fTcUz #LiverTwitter #LiverDisease @rabataller @RautouE

Any daily alcohol consumption is associated with certain cancers, and the risk of cancer increases with higher alcohol intake. This JAMA Insights discusses the evidence related to the US Surgeon General’s Advisory on alcohol and cancer risk. https://t.co/PAGkysHfA2

🍷 Associations between alcohol intake and #liver-related events vary across drinking categories, with those at higher genetic risk for #HepaticSteatosis being more susceptible to alcohol’s effects. Learn more at https://t.co/KPlXYxIAvR

📑 Moderate alcohol-associated hepatitis: A real-world multicenter study‼️ mAH has ⬆️ 💀 rates, driven by age, organ failure, infections, and variceal 🩸 . Current risk scores perform poorly in mAH https://t.co/oi9ZNE20oY